Status and phase
Conditions
Treatments
About
Study of elotuzumab in combination with pomalidomide and low dose dexamethasone (EPd Cohort) and elotuzumab in combination with nivolumab (EN Cohort) to assess the safety and efficacy of these combination therapies for treatment of relapsed or refractory MM patients.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
All subjects must have documented disease progression per IMWG criteria during or after their last anti-myeloma therapy.
ECOG Performance Status less than or equal to 2
Subject Re-enrollment: This study permits the re-enrollment of a subject that has discontinued the study as a pre-treatment failure (ie, has not been treated). If re-enrolled, the subject must be re-consented.
EPd Cohort:
EN Cohort:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply.
Primary purpose
Allocation
Interventional model
Masking
74 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal